Recognition that NYR's PCSK9 small moledule does what Evison and Suchowerska presented.
"Low-density lipoprotein cholesterol (LDL-C) causes atherosclerotic disease. This fact has been repeatedly demonstrated in experimental studies, epidemiological cohorts, randomised clinical trials of LDL-C lowering drugs, and studies employing Mendelian randomisation. Notably, the gradient of the relationship between LDL-C and outcomes of atherosclerotic disease becomes steeper with increasing duration of follow-up (in epidemiological studies) and treatment (in intervention trials). From this, it can be concluded that an individual’s risk of atherosclerotic disease is strongly determined by their cumulative lifelong exposure to LDL-C.
Accordingly, a significant long-term increased risk for coronary heart disease (CHD) and cardiovascular mortality has been reported in young adults with LDL-C ≥ 100 mg/dL (2.5 mmol/L). Therefore, in order to prevent atherosclerosis and its sequelae (myocardial infarction, ischemic stroke and peripheral arterial disease), it is necessary to act early in life.
Indeed, the early manifestations of atherosclerosis are often apparent in the third decade of life, a problem that is brought into stark reality by the early morbidity and mortality associated with familial hypercholesterolaemia (FH). Moreover, changes in plasma cholesterol levels have been found to be directly associated with cardiovascular disease (CVD) events in young adults.
Based on these findings, it is clear that, with respect to LDL-C, ‘lower is better, for longer’."
NYR Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)